Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 4Nelson Syndrome 2Multiple Myeloma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulinoma 1Hyperinsulinism 1

Interventions

antineoplaston AS 2-1 4antineoplaston A10 4Cyclophosphamide 4Cisplatin 4Temozolomide 3Radiotherapy 3dactolisib 2Vincristine 2Filgrastim 2Everolimus 2Etoposide 2Bevacizumab 2spartalizumab 1sargramostim 1pasireotide 1ganitumab 1gallium Ga 68 dotatate 1fosbretabulin 1cixutumumab 1belzutifan 1aldesleukin 1Topotecan 1Thiotepa 1TH 302 1Sunitinib 1Standard of Care 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors, Primitive × pasireotide × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡